Head and Neck Cancer Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Conditions: Biliary Tract Cancer; Breast Cancer; Cervical Cancer; Colon Cancer; Endometrial Cancer; Esophageal Cancer; Gastric Cancer; GastroEsophageal Cancer; Head and Neck Cancer; Hepatocellular Cancer; Non-small Cell Lung Cancer; Pancreatic Cancer; Prostate Cancer; Rectal Cancer; Renal Cancer; Thyroid Cancer Interventions: Drug: MDX2001 Sponsors: ModeX Therapeutics, An OPKO Health Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
Conditions: Advanced Solid Tumor; Melanoma; Lung Neoplasms; Head and Neck Neoplasms Interventions: Drug: KSQ-001EX; Drug: Interleukin-2; Drug: Cyclophosphamide; Drug: Fludarabine Sponsors: M.D. Anderson Cancer Center; KSQ Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Conditions: Metastatic Solid Tumor; Recurrent Solid Tumor; Advanced Solid Tumor; Urinary Bladder Neoplasm; Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Esophageal Cancer; Pancreatic Cancer; Ovarian Cancer; Cervical Cancer; Head and Neck Squamous Cell Carcinoma; Prostate Cancer; Renal Pelvis Cancer; Bladder Cancer Interventions: Drug: LY4101174 Sponsors: Eli Lilly and Company; Loxo Oncology, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials

PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Conditions: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Cancer; Recurrent Head and Neck Cancer; Metastatic Head-and-neck Squamous-cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma Interventions: Biological: PD-L1 t-haNK; Drug: Cetuximab; Biological: N-803 Sponsors: Glenn J. Hanna; ImmunityBio, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 2, 2024 Category: Research Source Type: clinical trials

Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas
Conditions: Squamous Cell Carcinoma of the Head and Neck; Squamous Cell Carcinoma of the Anus Interventions: Other: Multiparameter analysis of each sample Sponsors: National Cancer Institute, Naples Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials

Phase 1B of TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
Conditions: Squamous Cell Carcinoma of Head and Neck; Metastatic Squamous Cell Carcinoma Interventions: Biological: TBio-4101; Drug: Pembrolizumab; Drug: Platinum based chemotherapy; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Aldesleukin Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Turnstone Biologics, Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials

TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
Conditions: Squamous Cell Carcinoma of Head and Neck; Metastatic Squamous Cell Carcinoma Interventions: Biological: TBio-4101; Drug: Pembrolizumab; Drug: Platinum based chemotherapy; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Aldesleukin Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Turnstone Biologics, Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials

A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer
Conditions: Solid Tumor, Adult Interventions: Drug: BH009 Sponsors: Zhuhai Beihai Biotech Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials

Analysis of HPV and Biomarkers Present in the Biological Fluids of Patients Suffering From Head and Neck Cancer as a Non-invasive Strategy for Detecting Recurrence
Conditions: Head and Neck Tumors Interventions: Diagnostic Test: Collection and use of tissue samples, blood and saliva Sponsors: Regina Elena Cancer Institute; University of Milan; Istituti Tumori Giovanni Paolo II Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Conditions: Squamous Cell Carcinoma of the Head and Neck; Oropharynx; Human Papillomavirus Viruses; Drug Therapy; Cancer Vaccine Interventions: Drug: Docetaxel; Drug: Cisplatin; Drug: PRGN-2009 Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2024 Category: Research Source Type: clinical trials

ctDNA and MRI Parameters in Head and Neck Cancer
Conditions: Head and Neck Neoplasms; Carcinoma, Squamous Interventions: Other: Blood draw, MRI Sponsors: Franziska Eckert Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials

Adaptive Radiotherapy in Head and Neck Tumor Patients
Conditions: Head and Neck Neoplasms; Head and Neck Cancer; Adaptive Radiotherapy; Optimization Interventions: Radiation: Adaptive Radiotherapy; Radiation: image guided radiotherapy without online adaptation Sponsors: University Hospital, Essen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials

Prospective Validation of Adaptive Radiotherapy (ART) in Patients With Head and Neck Tumors
Conditions: Head and Neck Cancer; Adaptive Radiotherapy; Radiation; Optimized Treatment; Protection of Organs at Risk; Dysphagia Reduction Interventions: Radiation: Adaptive Radiotherapy Sponsors: University Hospital, Essen Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 19, 2024 Category: Research Source Type: clinical trials

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
Conditions: Locally Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Refractory Head and Neck Squamous Cell Carcinoma Interventions: Drug: Losartan; Biological: Pembrolizumab; Radiation: Stereotactic Body Radiation Therapy Sponsors: Shyam S.D. Rao; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials

A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
Conditions: Head and Neck Cancer Interventions: Drug: Toripalimab; Radiation: Radiation Therapy; Drug: Cisplatin Sponsors: Tianjin Medical University Cancer Institute and Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials